Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988664013> ?p ?o ?g. }
- W2988664013 endingPage "5555" @default.
- W2988664013 startingPage "5555" @default.
- W2988664013 abstract "Introduction Lenalidomide (Len) and low-dose Dexamethasone (dex) (Rd) in continuous is a new standard of care for elderly newly-diagnosed multiple myeloma (NDMM) patients (pts), as established by FIRST trial (Facon et al, Blood 2018). Methods and results This is a retrospective, multicentric study conducted in Italy with the aim of evaluating efficacy and tolerability of Rd in a real-life population. Thirty-seven centers were involved and data of 429 pts are available. Pts were considered eligible for the study when completing at least 2 cycles of Rd regimen. Table 1 summarizes the characteristics of pts at time of MM diagnosis. Median age was 78 years (range 57-92), 36.6% had an ECOG PS≥2, creatinine clearance (ClCr) was <30 ml/min in 7.1% of pts. 16, 30 and 54% resulted respectively fit, unfit and frail by IMWG Frailty score. ISS was respectively I, II and III in 27.5, 40.5 and 32% while R-ISS was I, II and III in 31.8, 42.4 and 25.8% of pts. t(4;14), t(14;16), del(17p) or amp(1q) by FISH were respectively found in 9.2%, 5.5%, 5.8% and 36.6% of pts. Extramedullary disease (EMD) was documented in 11% of pts. After a median follow-up of 11 months, most pts are still on treatment (60,4%), the median number of administered cycles was 7 (range 2-33). Overall response rate (ORR, ≥PR) was 74.5% with 34.1% of pts obtaining at least a VGPR. Clinical Benefit Rate (CBR, including minimal responses) was 83.3%. Responses were rapid with median time to first and to best response respectively of 1.8 (range 1-8) and 5 (1-26) months. Median OS and PFS were not reached with a 1-y and 2-y OS of 84.8 and 73.8% and a 1-y and 2-y PFS of 78.6 and 65%. Median EFS was 19.8 months. In univariate analysis, factors significatively impairing ORR were frailty (fit/unfit/frail 91.2/77/55.9%, p<0.001), ECOG (0-1/>2 81.7/61.6%, p<0.001), presence of t(4;14) (52.9 vs 76.7%, p=0.033) and amp(1q) (53.4 vs 83.5, p<0.001), R-ISS (3 vs 2-1 55.3 vs 72.6%, p=0.027), LDH > upper level of normal (ULN) (65.8 vs 77%, p=0.034). 1-y PFS is significantly shorter in pts with lower ECOG (0-1 vs 2, 66.5 vs 84.8%, p<0.001), higher frailty score (fit/unfit/frail 100/86.4/66.6%, p=0.01), higher ISS (I-II-III 88.4-79.1-68.5%, p=0.002) and R-ISS (I-II-III 75.5-88-50.5% p=0.02), LDH >ULN (66.4 vs 83.2%, p=0.02), lower ClCr (<30/30-50/>50 57.2/81.3/80.1%, P=0.01), presence of t(14;16) (42.9 vs 80.4% p=0.01) and amp(1q) (63.5 vs 85.6%, p=0.01); factor impairing OS are ECOG (0-1/>2 93.4 vs 69.4%, p<0.001), frailty (fit/unfit/frail 100/90.5/75.3% p=0.001), higher ISS (I-II-III 93.6/87.8/74.6%, p=0.006) and R-ISS (I-II-III 87/93/72%, p<0.001)), LDH >ULN (75.1 vs 97.1, p=0004), impaired ClCr (<30/30-50/>50 64/83.7/88.2%, p<0.001); EFS was affected by ECOG (0-1/>2 74.2 vs 47.3%, p<0.001), frailty (fit/unfit/frail 83.4/74.5/52% p=0.09), R-ISS (I-II-III 61.4/74.9/37.5% p=0.006), presence of t(14;16) (35.5 vs 67.8% p=0.08) or amp(1q) (50.1 vs 69% p=0.02). In multivariate analysis ORR is significantly correlated with ECOG>2 (p=0.05), LDH >ULN (p=0.005) and presence of amp1q (p=0.006); PFS was significantly affected by R-ISS III (p=0.04), LDH >ULN (P=0.01) and ClCr<30 (p=0.006) and EFS by R-ISS III (p=0.002); only ECOG>2 still impact on OS (p<0.0001) Dose reduction of Len or dex was required respectively in 20.7% and 22.1% and 39.2% needed cycle delay for adverse events (AEs). Grade 3-4 (G3-4) AEs occurred in 52% of pts with 30.9 and 36.6% having at least a hematological or extra-hematological G3-4 AE. In particular, 17.9 and 16.6% of pts had severe neutropenia and anemia while the most common non-hematological AEs were infections (25.8%, G3-4 12.2%), mainly involving respiratory tract (71.2%). Gastroenteric and cutaneous AEs were quite common (22.1 and 19.2%), mainly diarrhea and itching, but in the vast majority were mild. G3-4 asthenia was present in 22.8% of pts. Although 99% of pts was given antithrombotic prophylaxis, 8.5% had a thromboembolic event, a third of severe entity. G-CSF and EPO analogs were required in 27.4 and 26% of pts. Conclusion Real-life data confirm efficacy and tolerability of Rd in elderly NDMM pts. Performance status by ECOG and IMWG frailty score and severe renal impairment but not age itself act as limiting factors affecting outcome. These data must be confirmed by longer follow-up. Disclosures Conticello: Celgene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding. Mangiacavalli:Janssen cilag: Consultancy; celgene: Consultancy; Amgen: Consultancy. Zambello:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Belotti:Amgen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees. Molteni:Celgene: Membership on an entity's Board of Directors or advisory committees. Aquino:Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Del Fabro:Janssen: Consultancy. Galli:Leadiant (Sigma-Tau): Honoraria; Janssen: Honoraria; Bristol-Myers Squibb: Honoraria; Takeda: Honoraria; Celgene: Honoraria." @default.
- W2988664013 created "2019-11-22" @default.
- W2988664013 creator A5000981765 @default.
- W2988664013 creator A5003225344 @default.
- W2988664013 creator A5003679742 @default.
- W2988664013 creator A5004133566 @default.
- W2988664013 creator A5005070661 @default.
- W2988664013 creator A5005073852 @default.
- W2988664013 creator A5005074422 @default.
- W2988664013 creator A5008096525 @default.
- W2988664013 creator A5011287280 @default.
- W2988664013 creator A5015338533 @default.
- W2988664013 creator A5016021915 @default.
- W2988664013 creator A5018769545 @default.
- W2988664013 creator A5021352592 @default.
- W2988664013 creator A5025049786 @default.
- W2988664013 creator A5025699500 @default.
- W2988664013 creator A5028704583 @default.
- W2988664013 creator A5029067718 @default.
- W2988664013 creator A5029476940 @default.
- W2988664013 creator A5040128855 @default.
- W2988664013 creator A5040930723 @default.
- W2988664013 creator A5044763057 @default.
- W2988664013 creator A5045579010 @default.
- W2988664013 creator A5050469395 @default.
- W2988664013 creator A5050601860 @default.
- W2988664013 creator A5053043046 @default.
- W2988664013 creator A5054921768 @default.
- W2988664013 creator A5060752899 @default.
- W2988664013 creator A5062777249 @default.
- W2988664013 creator A5063250983 @default.
- W2988664013 creator A5066814162 @default.
- W2988664013 creator A5072331165 @default.
- W2988664013 creator A5072657141 @default.
- W2988664013 creator A5072928867 @default.
- W2988664013 creator A5076929140 @default.
- W2988664013 creator A5077047252 @default.
- W2988664013 creator A5077270786 @default.
- W2988664013 creator A5079570737 @default.
- W2988664013 creator A5079910766 @default.
- W2988664013 creator A5085292624 @default.
- W2988664013 creator A5086743021 @default.
- W2988664013 creator A5090123367 @default.
- W2988664013 date "2019-11-13" @default.
- W2988664013 modified "2023-09-28" @default.
- W2988664013 title "Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability" @default.
- W2988664013 doi "https://doi.org/10.1182/blood-2019-125098" @default.
- W2988664013 hasPublicationYear "2019" @default.
- W2988664013 type Work @default.
- W2988664013 sameAs 2988664013 @default.
- W2988664013 citedByCount "0" @default.
- W2988664013 crossrefType "journal-article" @default.
- W2988664013 hasAuthorship W2988664013A5000981765 @default.
- W2988664013 hasAuthorship W2988664013A5003225344 @default.
- W2988664013 hasAuthorship W2988664013A5003679742 @default.
- W2988664013 hasAuthorship W2988664013A5004133566 @default.
- W2988664013 hasAuthorship W2988664013A5005070661 @default.
- W2988664013 hasAuthorship W2988664013A5005073852 @default.
- W2988664013 hasAuthorship W2988664013A5005074422 @default.
- W2988664013 hasAuthorship W2988664013A5008096525 @default.
- W2988664013 hasAuthorship W2988664013A5011287280 @default.
- W2988664013 hasAuthorship W2988664013A5015338533 @default.
- W2988664013 hasAuthorship W2988664013A5016021915 @default.
- W2988664013 hasAuthorship W2988664013A5018769545 @default.
- W2988664013 hasAuthorship W2988664013A5021352592 @default.
- W2988664013 hasAuthorship W2988664013A5025049786 @default.
- W2988664013 hasAuthorship W2988664013A5025699500 @default.
- W2988664013 hasAuthorship W2988664013A5028704583 @default.
- W2988664013 hasAuthorship W2988664013A5029067718 @default.
- W2988664013 hasAuthorship W2988664013A5029476940 @default.
- W2988664013 hasAuthorship W2988664013A5040128855 @default.
- W2988664013 hasAuthorship W2988664013A5040930723 @default.
- W2988664013 hasAuthorship W2988664013A5044763057 @default.
- W2988664013 hasAuthorship W2988664013A5045579010 @default.
- W2988664013 hasAuthorship W2988664013A5050469395 @default.
- W2988664013 hasAuthorship W2988664013A5050601860 @default.
- W2988664013 hasAuthorship W2988664013A5053043046 @default.
- W2988664013 hasAuthorship W2988664013A5054921768 @default.
- W2988664013 hasAuthorship W2988664013A5060752899 @default.
- W2988664013 hasAuthorship W2988664013A5062777249 @default.
- W2988664013 hasAuthorship W2988664013A5063250983 @default.
- W2988664013 hasAuthorship W2988664013A5066814162 @default.
- W2988664013 hasAuthorship W2988664013A5072331165 @default.
- W2988664013 hasAuthorship W2988664013A5072657141 @default.
- W2988664013 hasAuthorship W2988664013A5072928867 @default.
- W2988664013 hasAuthorship W2988664013A5076929140 @default.
- W2988664013 hasAuthorship W2988664013A5077047252 @default.
- W2988664013 hasAuthorship W2988664013A5077270786 @default.
- W2988664013 hasAuthorship W2988664013A5079570737 @default.
- W2988664013 hasAuthorship W2988664013A5079910766 @default.
- W2988664013 hasAuthorship W2988664013A5085292624 @default.
- W2988664013 hasAuthorship W2988664013A5086743021 @default.
- W2988664013 hasAuthorship W2988664013A5090123367 @default.
- W2988664013 hasConcept C126322002 @default.
- W2988664013 hasConcept C141071460 @default.
- W2988664013 hasConcept C197934379 @default.
- W2988664013 hasConcept C2776063141 @default.
- W2988664013 hasConcept C2776364478 @default.